PLGA, PLA, PCL polymers for Controlled Drug Delivery

Introduction: PLGA vs PLGA-PEG for nanoparticle drug delivery is one of the first formulation decisions a sponsor faces when designing […]

Introduction Poly(lactic-co-glycolic acid) characterization provides the essential analytical data required to control degradation rates, optimize drug entrapment, and ensure batch-to-batch

Introduction: PLA nanoparticle formulation for targeted oncology delivery is one of the more demanding areas of parenteral drug development, because

Introduction The primary biophysical distinction between PLGA 50:50 and PLGA 75:25 is defined by their monomer composition, specifically the ratio

Introduction Poly(lactic-co-glycolic acid) (PLGA)-based particulate delivery systems offer a highly biocompatible and biodegradable platform for protecting fragile biomolecules while enabling

PLGA Microsphere Formulation Development — Case Study Redesign :root{ –ink:#101d2b; –paper:#f6f5f1; –panel:#ffffff; –teal:#1b6e71; –teal-dim:#e4eeed; –amber:#b8802e; –amber-dim:#f4e9da; –slate:#57626e; –line:#e1ddd2; –line-dark:#28394a; }

Introduction Professional PLGA Microsphere Scale-Up Services provide the essential engineering, analytical, and manufacturing infrastructure needed to successfully transition complex poly(lactic-co-glycolic

Introduction The formation of an acidic microenvironment during the degradation of poly(lactic-co-glycolic acid) (PLGA) matrices represents one of the most

Introduction: PLGA for pulmonary drug delivery has become a focal point for formulators seeking to extend the therapeutic window of

Introduction Characterization Methods for PLGA Microspheres involve a comprehensive range of advanced analytical techniques used to assess the physicochemical properties,